购物车
- 全部删除
- 您的购物车当前为空
Zotiraciclib(又名TG02和SB1317)是一种新型小分子化合物,具有强效的CDK/JAK2/FLT3抑制作用。该化合物可通过抑制周期蛋白依赖性激酶9(CDK9),耗竭Myc来治疗能穿越血脑屏障的癌症。Zotiraciclib是正在研究的众多CDK抑制剂之一,其他针对CDK9的化合物,用于治疗急性髓细胞性白血病的还包括alvocidib和atuveciclib。许多癌症中的Myc过表达是一个已知因素,其中80%的胶质母细胞性瘤展现此特性。
Zotiraciclib(又名TG02和SB1317)是一种新型小分子化合物,具有强效的CDK/JAK2/FLT3抑制作用。该化合物可通过抑制周期蛋白依赖性激酶9(CDK9),耗竭Myc来治疗能穿越血脑屏障的癌症。Zotiraciclib是正在研究的众多CDK抑制剂之一,其他针对CDK9的化合物,用于治疗急性髓细胞性白血病的还包括alvocidib和atuveciclib。许多癌症中的Myc过表达是一个已知因素,其中80%的胶质母细胞性瘤展现此特性。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
10 mg | 询价 | 10-14周 | |
50 mg | 询价 | 10-14周 |
产品描述 | Zotiraciclib (also known as TG02 and SB1317) is an innovative small-molecule compound with potent inhibitory effects on CDK, JAK2, and FLT3. By inhibiting cyclin-dependent kinase 9 (CDK9) and depleting Myc, it serves as a treatment for cancers that can penetrate the blood-brain barrier. Zotiraciclib is one of the numerous CDK inhibitors under investigation; other compounds targeting CDK9, utilized for treating acute myeloid leukemia, include alvocidib and atuveciclib. Myc overexpression is a known factor in many cancers, with 80% of glioblastomas exhibiting this characteristic. |
分子量 | 564.59 |
分子式 | C29H32N4O8 |
CAS No. | 1204918-73-9 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
评论内容